| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 2,077,100 | 1,367,900 | 703,700 | 1,649,500 |
| Depreciation and loss on disposal of property, plant, and equipment | 446,300 | 289,600 | 137,500 | 323,700 |
| Amortization of intangible assets | 9,900 | 6,600 | 3,400 | 13,600 |
| Gain on investments, accretion of discounts, and amortization of premiums on investments, net | 42,300 | 27,400 | 17,700 | 38,200 |
| Deferred income taxes | -58,600 | 29,400 | -100 | 104,500 |
| Share-based compensation expense | 584,900 | 381,400 | 185,200 | 499,800 |
| Amortization of contract acquisition assets | 27,400 | 17,800 | 8,700 | 27,000 |
| Accounts receivable | 34,200 | 44,100 | -3,600 | 21,800 |
| Inventory | 810,400 | 494,200 | 211,100 | 650,900 |
| Prepaids and other assets | 248,900 | 141,800 | 7,800 | 79,600 |
| Accounts payable | 97,000 | 72,400 | 83,100 | 21,200 |
| Accrued compensation and employee benefits | -80,200 | -114,900 | -226,000 | -58,900 |
| Deferred revenue | 47,600 | 48,800 | 37,000 | -6,100 |
| Other liabilities | 5,200 | -35,700 | -118,100 | 17,600 |
| Net cash provided by operating activities | 2,138,000 | 1,297,000 | 581,600 | 1,592,400 |
| Purchase of investments | 790,900 | 691,800 | 519,800 | 3,709,600 |
| Proceeds from sales of investments | 249,100 | 249,100 | 0 | 100,200 |
| Proceeds from maturities of investments | 1,795,500 | 1,190,000 | 849,900 | 2,400,000 |
| Purchase of property, plant, and equipment | 377,300 | 271,900 | 116,600 | 799,200 |
| Acquisition of businesses, net of cash, and intellectual property and other investing activities | 1,200 | 1,200 | - | 0 |
| Net cash provided by (used in) investing activities | 875,200 | 474,200 | 213,500 | -2,008,600 |
| Proceeds from issuance of common stock relating to employee stock plans | 273,700 | 183,700 | 134,300 | 367,500 |
| Taxes paid related to net share settlement of equity awards | 406,000 | 386,300 | 370,100 | 257,500 |
| Repurchase of common stock | 2,094,300 | 181,000 | - | 0 |
| Cash dividends paid by joint venture to noncontrolling interest | 0 | 0 | - | 8,000 |
| Payment of deferred purchase consideration | 0 | 0 | 0 | 500 |
| Net cash provided by (used in) financing activities | -2,226,600 | -383,600 | -235,800 | 101,500 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 500 | -3,500 | -4,500 | -9,100 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 787,100 | 1,384,100 | 554,800 | -323,800 |
| Cash and cash equivalents at beginning of period | 2,062,400 | 2,062,400 | 2,062,400 | 2,770,100 |
| Cash and cash equivalents at end of period | 2,849,500 | 3,446,500 | 2,617,200 | 2,446,300 |
INTUITIVE SURGICAL INC (ISRG)
INTUITIVE SURGICAL INC (ISRG)